A Phase 2 interventional study of ZW25 (Zanidatamab) and Palbociclib in HER2+/HR+ Breast Cancer, sponsored by Jazz Pharmaceuticals. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 286 under way, 84 of them phase 3. Breast Neoplasms · Spain.
Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 643rd largest by enrollment of the 805 interventional ones that give a count, is one of 59 that started in 2020, is one of 248 in phase 2, and was the 548th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Sites in Spain
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in Spain, United States, Belgium and 5 more countries
Ages 18+
Kenko Imalytics S.L. · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 326 · Phase 3 224 · Phase 4 13
First in 1996; this study’s year is marked. 59 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 151 across the 805 interventional studies, 200 across the 97 observational. Of the 575 that completed or were terminated, 291 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
533 of 905 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 5 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
80 of the studies in Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
Add all 80 to your calendar (.ics) → With an account.
Among the 905 studies in Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.
Part 1 of the study will first evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant and will confirm the recommended doses (RDs) of ZW25 and palbociclib in this combination. Part 2 of the study will evaluate the anti-tumor activity of the combination of ZW25 with palbociclib plus fulvestrant at the RD level in patients with HER2-positive, HR-positive advanced breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter.
Drug: ZW25 (Zanidatamab) · Drug: Palbociclib · Drug: Fulvestrant
Administered intravenously
Administered orally
Administered as an intramuscular injection
Number of Participants With Dose-Limiting Toxicities
Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol.
Time frame: Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events
A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0.
Time frame: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
Progression-free Survival 6
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).
Time frame: 6 months from first dose of all study drugs to the date of documented disease progression or death
Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest
A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis.
Time frame: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
Maximum Serum Concentration Steady State of ZW25
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).
Time frame: End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
Trough Concentration Steady State of ZW25
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).
Time frame: Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
Number of Participants With Anti-drug Antibodies (ADAs) Post-baseline
Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA").
Time frame: Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
Objective Response Rate
Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1.
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
Duration of Response
DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis.
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
Disease Control Rate
Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated.
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
Progression-free Survival
Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
Overall Survival
OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause.
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
Incidence of Abnormal Hepatic Lab Values
Time frame: From first dose of treatment up to end of study, approximately 5 years 20 days
A total of 51 participants who met all eligibility criteria were enrolled and received treatment. This study was officially completed on 30 June 2025. All efficacy and safety analyses were conducted as planned.
| Milestone | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Started | 8 |
| Completed | 0 |
| Not completed | 8 |
| Withdrew: Death | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Started | 43 |
| Completed | 0 |
| Not completed | 43 |
| Withdrew: Death | 22 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Sponsor decision | 16 |
Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol.
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Number of Participants With Dose-Limiting Toxicities | 1 |
A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0.
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Any Blood and Lymphatic System Disorders AE | 20 |
| Neutropenia | 16 |
| Anaemia | 6 |
| Thrombocytopenia | 3 |
| Leukopenia | 1 |
| Any Gastrointestinal Disorder AE | 13 |
| Diarrhoea | 8 |
| Abdominal pain | 1 |
| Duodenal ulcer | 1 |
| Gastric ulcer | 1 |
| Nausea | 1 |
| Small intestinal obstruction | 1 |
| Stomatitis | 1 |
| Vomiting | 1 |
| Any Investigation AE | 12 |
| Neutrophil count decreased | 11 |
| Ejection fraction decreased | 1 |
| Transaminases increased | 1 |
| White blood cell count decreased | 2 |
| Any Metabolism and Nutrition Disorder AE | 8 |
| Hypokalaemia | 4 |
| Hypomagnesaemia | 3 |
| Hypercalcaemia | 2 |
| Any General Disorders and Administration Site Conditions AE | 2 |
| Fatigue | 1 |
| Pyrexia | 1 |
| Asthenia | 1 |
| Any Infections and Infestations AE | 2 |
| COVID-19 pneumonia | 1 |
| Psoas abscess | 1 |
| Staphylococcal bacteraemia | 1 |
| Cellulitis | 1 |
| Any Respiratory, Thoracic and Mediastinal Disorder AE | 2 |
| Pleural effusion | 1 |
| Pneumothorax | 1 |
| Pulmonary embolism | 1 |
| Any Renal and Urinary Disorder AE | 1 |
| Acute kidney injury | 1 |
| Any Skin and Subcutaneous Tissue Disorder AE | 1 |
| Rash maculo-papular | 1 |
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Progression-free Survival 6 | 34 |
A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis.
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| TEAE | 51 |
| Grade 3 or higher TEAEs | 39 |
| SAE | 9 |
| AESI | 5 |
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).
| ug/mL | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Maximum Serum Concentration Steady State of ZW25 | 726.80 ± 147.66 |
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA).
| ug/mL | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Trough Concentration Steady State of ZW25 | 253.47 ± 54.0 |
Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA").
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Number of patients positive for treatment-emergent ADA | 10 |
| Number of patients negative for treatment-emergent ADA | 37 |
Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1.
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Objective Response Rate | 16 |
DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis.
| months | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Duration of Response | 13.16 (9.20 to 22.34) |
Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated.
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Disease Control Rate | 42 |
Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.
| months | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Progression-free Survival | 9.30 (8.38 to 14.42) |
OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause.
| months | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Overall Survival | 32.20 (24.18 to NA) |
| Participants | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Participants with ALT > 5 x ULN | 1 |
| Participants with AST > 5 x ULN | 2 |
| Participants with AST or ALT > 3 x ULN and ≤ 5 x ULN | 4 |
| Participants with ALP > 2 x ULN | 10 |
| Participants with total bilirubin > 2 x ULN | 1 |
| Patients w/ potential Drug Induced Liver Injury: AST or ALT > 3 x ULN & total bilirubin > 2 x ULN | 1 |
| Patients w/ potential Hy's law: AST or ALT > 3 x ULN & total bilirubin > 2 x ULN and ALP < 2 x ULN | 0 |
Collected over Adverse events were collected from the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZW25 (Zanidatamab) + Palbociclib + Fulvestrant | 27/51 (52.9%) | 9/51 (17.6%) | 51/51 (100%) |
| Event | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Duodenal ulcerGastrointestinal disorders | 1/51 |
| Gastric ulcerGastrointestinal disorders | 1/51 |
| Small intestinal obstructionGastrointestinal disorders | 1/51 |
| COVID-19Infections and infestations | 1/51 |
| COVID-19 pneumoniaInfections and infestations | 1/51 |
| Psoas abscessInfections and infestations | 1/51 |
| Staphylococcal bacteraemiaInfections and infestations | 1/51 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/51 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/51 |
| AnaemiaBlood and lymphatic system disorders | 1/51 |
| Event | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| DiarrhoeaGastrointestinal disorders | 47/51 |
| NauseaGastrointestinal disorders | 29/51 |
| StomatitisGastrointestinal disorders | 21/51 |
| AstheniaGeneral disorders | 19/51 |
| NeutropeniaBlood and lymphatic system disorders | 19/51 |
| VomitingGastrointestinal disorders | 18/51 |
| AnaemiaBlood and lymphatic system disorders | 16/51 |
| Neutrophil count decreasedInvestigations | 14/51 |
| Decreased appetiteMetabolism and nutrition disorders | 12/51 |
| Abdominal painGastrointestinal disorders | 11/51 |
The baseline demographic characteristics were assessed in the Safety Analysis Set.
| Age, Continuous(years) | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Mean | 54.7 ± 10.9 |
| Sex: Female, Male(Participants) | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Female | 49 |
| Male | 2 |
| Race/Ethnicity, Customized(Participants) | ZW25 (Zanidatamab) + Palbociclib + Fulvestrant |
|---|---|
| Asian | 2 |
| Black or African American | 1 |
| White | 42 |
| Multiple | 1 |
| Other | 1 |
| Unknown | 3 |
| Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Apr 2023, 34 months.
Results were first posted in Aug 2024, 1 year 3 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 34 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanidatamab